Glenn P. Sblendorio

Chief Executive Officer & President at IVERIC bio, Inc.

Glenn P. Sblendorio

Glenn P. Sblendorio

Chief Executive Officer & President at IVERIC bio, Inc.

Overview
Career Highlights

Roche Molecular Systems, Inc.
Hoffmann-La Roche, Inc.
Millennium Venture Management LLC

RelSci Relationships

2684

Number of Boards

4

Birthday

1956

Age

64

Relationships
RelSci Relationships are individuals Glenn P. Sblendorio likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Imagen Biotech, Inc.

Relationship likelihood: Strong

Former Co-Chair, Life Sciences Group at Wilmer Cutler Pickering Hale and Dorr LLP

Relationship likelihood: Strong

Global Head of Life Sciences at The Blackstone Group, Inc.

Relationship likelihood: Strong

Director at IVERIC bio, Inc.

Relationship likelihood: Strong

Co-Founder at Intercept Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder & Chief Executive Officer at Inozyme Pharma, Inc.

Relationship likelihood: Strong

Chief Strategy Officer at China Ophthalmology Focus Limited

Relationship likelihood: Strong

Managing Director at Clarus Ventures LLC

Relationship likelihood: Strong

Managing Partner NOVO Ventures at Novo Holding A/S

Relationship likelihood: Strong

Former Chairman of the Board, Chief Executive Officer at Amicus Therapeutics, Inc.

Relationship likelihood: Strong

Paths to Glenn P. Sblendorio
Potential Connections via
Relationship Science
You
Glenn P. Sblendorio
Chief Executive Officer & President at IVERIC bio, Inc.
Career History
2002 - 2005

Eyetech Pharmaceuticals, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York.

Head-Finance & Controller
Prior

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Chief Financial Officer & Vice President-Finance
1992 - 1993

Roche Molecular Systems, Inc. develops and produces molecular-based diagnostic tests and automated testing platforms. It specializes in oncology, virology, microbiology and blood screening tests areas. The firm's customers include researchers, physicians, patients, hospitals, laboratories and blood banks. The company is headquartered in Pleasanton, CA.

Boards & Committees
Member, Board of Directors
2014 - Current
Member, Board of Directors
2006 - Current
Independent Director
2013 - Prior
Political Donations
$1,000
2013
$2,500
2012
$2,500
2011
Transactions
Details Hidden

IVERIC bio, Inc. raised money in a private placement transaction

Details Hidden

The Medicines Co. purchases Rempex Pharmaceuticals, Inc.

Details Hidden

The Medicines Co. purchases Targanta Therapeutics Corp.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Glenn P. Sblendorio. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Glenn P. Sblendorio's profile does not indicate a business or promotional relationship of any kind between RelSci and Glenn P. Sblendorio.